<DOC>
	<DOCNO>NCT02196077</DOCNO>
	<brief_summary>This Phase IIb , randomize , double blind , chronic dosing ( 28 day ) , four period , five treatment , incomplete block , crossover design subject moderate severe COPD . The overall objective demonstrate combination budesonide ( BD ; PT008 ) formoterol fumarate ( FF ; PT005 ) metered-dose inhaler ( MDI ) ; ( BFF MDI ; PT009 ) provide benefit lung function compare BD MDI subject moderate severe COPD .</brief_summary>
	<brief_title>Efficacy Safety Study PT009 , PT008 , PT005 Subjects With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Informed Consent Form ( ICF ) prior study related procedure COPD Diagnosis : Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Tobacco Use : Current former smoker history least 10 pack year cigarette smoke Women nonchildbearing potential medically acceptable contraception woman childbearing potential male female partner childbearing potential Severity Disease : Subjects establish clinical history COPD severity define : FEV1/forced vital capacity ( FVC ) ratio &lt; 0.70 ; At Screening ( Visit 1a/b ) , post bronchodilator FEV1 must &lt; 80 % predict normal value , calculate use NHANES III ( Third National Health Nutrition Examination Survey ) reference equation ; measure FEV1 must also â‰¥30 % predict normal value ; Visit 2 , average 60 minute 30 minute pre dose FEV1 assessment must &lt; 80 % predict normal value calculate use NHANES III reference equation Screening clinical laboratory test must acceptable Investigator Screening ECG must acceptable Investigator Chest x ray computerize tomography ( CT ) scan within 6 month prior Visit 1a must acceptable Investigator . Significant diseases COPD , ie. , disease condition , opinion Investigator , may put subject risk participation study may influence either result study subject 's ability participate study Pregnancy , nurse female subject , subject try conceive , use medically acceptable form contraception Asthma : Subjects primary diagnosis asthma ( Note : Subjects prior history asthma eligible COPD currently primary diagnosis ) . Alpha 1 Antitrypsin Deficiency : Subjects alpha 1 antitrypsin deficiency cause COPD Active pulmonary disease active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , primary pulmonary hypertension , interstitial lung disease , uncontrolled sleep apnea ( ie. , opinion Investigator severity disorder would impact conduct study ) Clinically significant neurologic , cardiovascular , hepatic , renal , endocrinologic , pulmonary , hematological , psychiatric , medical illness would interfere participation study Poorly Controlled COPD History ECG abnormalities Cancer complete remission least 5 year Clinically significant , symptomatic prostatic hypertrophy Male subject transurethral resection prostate full resection prostate within 6 month prior Screening Clinically significant bladder neck obstruction urinary retention Inadequately treat glaucoma History allergic reaction hypersensitivity drug component formulation use study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Budesonide formoterol inhalation aerosol</keyword>
</DOC>